


VISCHER IS ADVISING REDBIOTEC

Posted on 18 May 2020



Category: [Rumors](#)

Tags: [News](#), [Redbiotec](#), [Vischer](#)



Redbiotec, a Swiss developer of a therapeutic vaccine for genital herpes, is planning to close a CHF 9m Series A round in 2020, CEO Christian Schaub [told Mergermarket](#). The Zurich-based company will use the proceeds to advance its genital herpes (HSV-2) immunotherapy program into Phase I/IIa clinical studies.

VISCHER is Redbiotec's legal advisor.